ÂÜÀòÂÒÂ×

Oskar has a broad biotech and business background and is currently partner at BioGeneration Ventures. Oskar started his career in McKinsey & Company as a management consultant. After that he held positions in Crucell, first in business development and later he became responsible for the Pediatric Franchise. After the acquisition of Crucell by Johnson & Johnson, Oskar led the Vaccines & Infectious Diseases business unit in Johnson & Johnson’s pharma joint venture Xian Janssen in Beijing, China. Prior to joining BioGeneration Oskar was Chief Commercial Officer of Avantium, a leading chemical technology company and a forerunner in renewable chemistry.

Oskar has a degree in chemical engineering from Twente University and holds a MBA from INSEAD.

Oskar serves on several boards of companies in BioGeneration’s portfolio.